Abstract
To evaluate and compare the health-related quality of life (HRQOL) of patients with newly diagnosed CML in the first chronic phase (CML-CP1) receiving HLA-identical sibling donor (ISD) hematopoietic SCT (HSCT) or imatinib, a cross-sectional study that was part of a prospective cohort study at the Institute of Hematology, Peking University was performed. A total of 222 patients including 126 and 96 in the imatinib and ISD HSCT groups, respectively, were enrolled. HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey. The ISD HSCT group functioned significantly better on the role-physical functioning and mental health subscales, as well as the mental component summary (MCS) than the imatinib group. HRQOL was generally comparable to groups in the young population. Multivariate analysis showed that white blood cell count⩾30 × 109/L and plts count ⩾450 × 109/L were the major adverse factors affecting HRQOL in long-term survivors. Imatinib therapy was also an adverse factor affecting the MCS (odds ratio=1.7, P=0.032). Thus, long-term CML-CP1 survivors receiving ISD HSCT can attain desirable HRQOL comparable to or better than that of patients receiving imatinib.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011; 9: S1–S25.
Goldman JM . Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program 2009; 2009: 453–460.
Goldman JM . Treatment strategies for CML. Best Pract Res Clin Haematol 2009; 22: 303–313.
Pavlu J, Szydlo RM, Goldman JM, Apperley JF . Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011; 117: 755–763.
Oyekunle A, Klyuchnikov E, Ocheni S, Kröger N, Zander AR, Baccarani M et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 2011; 126: 30–39.
Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006 91: 513–521.
Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461–467.
Pasquini MC . Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology 2012; 17: S79–S82.
Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117: 5591–5599.
Goldman JM . How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828–2837.
Bumbea H, Vladareanu AM, Voican I, Cisleanu D, Barsan L, Onisai M . Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors—the first molecular targeted treatment. J Med Life 2010; 3: 162–166.
Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003; 21: 2138–2146.
Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A . Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 2011; 52: 1017–1023.
Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011; 118: 4554–4560.
Chang G, Orav EJ, McNamara TK, Tong MY, Antin JH . Psychosocial function after hematopoietic stem cell transplantation. Psychosomatics 2005; 46: 34–40.
Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA . Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 2002; 20: 2334–2343.
Jiang Q, Xu LP, Liu DH, Liu KY, Gale RP, Zhang MJ et al. Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. Leukemia 2013; 27: 2410–2413.
Ware JE, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A . Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995; 33: AS264–AS279.
Li L, Wang HM, Shen Y . Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health 2003; 57: 259–263.
Chen Z, Wang C, Xu X, Feng W . Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health 2009; 12: S85–S88.
Liang Y, Lai Y, Schwarzenberger P, Li Q, Ma J, Luo J et al. Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrowtransplantation for that disease? Biol Blood Marrow Transplant 2010; 16: 848–853.
Sutherland HJ, Fyles GM, Adams G, Hao Y, Lipton JH . Quality of life following bone marrow transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant 1997; 19: 1129–1136.
Duell T, van Lint MT, Ljungman P, Tichelli A, Socié G, Apperley JF et al. Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med 1997; 126: 184–192.
Bush NE, Donaldson GW, Haberman MH, Dacanay R, Sullivan KM . Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients. Biol Blood Marrow Transplant 2000; 6: 576–591.
Chiodi S, Spinelli S, Ravera G, Petti AR, Van Lint MT, Lamparelli T et al. Quality of life in 244 recipients of allogeneic bone marrow transplantation. Br J Haematol 2000; 110: 614–619.
Bevans MF, Marden S, Leidy NK, Soeken K, Cusack G, Rivera P et al. Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 101–109.
Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011; 29: 2827–2832.
Lakshmaiah K, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM et al. Chronic myeloid leukemia in children and adolescents: Results of treatment with imatinib mesylate. Leuk Lymphoma 2012; 53: 2430–2433.
Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908–916.
Bansal D, Shava U, Varma N, Trehan A, Marwaha RK . Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012; 59: 481–484.
Andolina JR, Neudorf SM, Corey SJ . How I treat childhood CML. Blood 2012; 119: 1821–1830.
Suttorp M, Yaniv I, Schultz KR . Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011; 17: S115–S122.
Weisser M, Ledderose G, Jochem Kolb H . Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade. Ann Hematol 2007; 86: 127–132.
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799.
Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90: 850–858.
Mo XD, Xu LP, Liu DH, Chen YH, Han W, Zhang XH et al. Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT. Bone Marrow Transplant 2012; 47: 1201–1205.
Acknowledgements
We thank the medical editors at Editage, who provided editing assistance to the authors during the preparation of this manuscript.This work was supported by the Key Program of National Natural Science Foundation of China (Grant No. 81230013) and the Beijing Municipal Science & Technology Commission (Z111107067311070).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Mo, XD., Jiang, Q., Xu, LP. et al. Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant 49, 576–580 (2014). https://doi.org/10.1038/bmt.2013.232
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2013.232
Keywords
This article is cited by
-
Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study
BMC Cancer (2018)
-
Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy
Journal of Cancer Research and Clinical Oncology (2017)
-
Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia
Journal of Cancer Research and Clinical Oncology (2017)
-
Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia
Current Hematologic Malignancy Reports (2016)
-
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Leukemia (2016)